Original articleDifferential gene expression identifies subgroups of ovarian carcinoma
Section snippets
Tissue samples
Tissue from 29 ovarian cancer samples (21 H-OVCA and 8 BL-OVCA) and 512 samples from 17 different types of nonmalignant tissues, including 59 cases of normal ovary, 14 normal adipose tissue, 25 reparative bone samples from degenerative joint disease, 5 samples of normal bone, 19 normal cervix, 41 normal colon, 25 normal liver, 36 normal lung, 21 normal kidney, 20 normal skeletal muscle, 90 normal myometrium, 12 normal skin, 12 normal small intestine, 7 normal stomach, 63 normal thymus, 59
Gene expression
Gene expression using the Affymetrix GeneChip U_133 microarray set was performed on all samples. About 6200 of the ∼40,000 gene fragments examined were present in all 21 samples in the set of H-OVCA samples (Fig 1, top panel). About 8000 gene fragments were present in all 8 samples of the BL-OVCA set (Fig 1, bottom panel).
Identification of ovarian cancer subsets
As heterogeneity in the biologic behavior of ovarian cancer is well known, the H-OVCA set was examined for the possible existence of subsets. A fold change analysis identified
Discussion
Ovarian carcinoma is variable in its clinical behavior, and gene expression is felt to underlie these differences. In this study, 2 major subsets of the H-OVCA samples were identified, termed H-OVCA-A and H-OVCA-B, based on gene expression patterns. These 2 subsets were identified by examining the expression levels of sets of genes that were differentially expressed among the sets of H-OVCA, BL-OVCA, and normal ovary samples.
It might be expected that H-OVCA samples with different biological
References (42)
The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes?
Gynecol Oncol
(1999)- et al.
Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause
Am J Obstet Gynecol
(2004) - et al.
Pathology of borderline (low malignant potential) ovarian tumours
Best Pract Res Clin Obstet Gynaecol
(2002) - et al.
Molecular characterisation of soft tissue tumours: a gene expression study
Lancet
(2002) - et al.
Differential gene expression in renal-cell cancer
J Lab Clin Med
(2002) - et al.
Characterization of sarcomas by means of gene expression
J Lab Clin Med
(2004) - et al.
Gene expression in aggressive fibromatosis
J Lab Clin Med
(2004) - et al.
Differential gene expression identifies subgroups of renal cell carcinoma
J Lab Clin Med
(2006) - et al.
Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses
Mol Cell Endocrinol
(2006) - et al.
Differential gene expression in ovarian carcinoma: identification of potential biomarkers
Am J Pathol
(2004)
Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling
Gynecol Oncol
Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives
Hum Pathol
Toward the development of a universal grading system for ovarian epithelial carcinomaI. Prognostic significance of histopathologic features—problems involved in the architectural grading system
Gynecol Oncol
Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system
Gynecol Oncol
Differential gene expression in uterine leiomyoma
J Lab Clin Med
Gene expression in giant-cell tumors
J Lab Clin Med
Cancer Facts and Figures 2006
The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin
Int J Gynecol Pathol
Ovarian tumor development: insights from ovarian embryogenesis
Eur J Gynaecol Oncol
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis
Am J Pathol
World Health Organization classification and nomenclature of ovarian cancer
Natl Cancer Inst Monogr
Cited by (33)
Radiomics and Radiogenomics of Ovarian Cancer: Implications for Treatment Monitoring and Clinical Management
2023, Radiologic Clinics of North AmericaOvarian cancer: An update on imaging in the era of radiomics
2019, Diagnostic and Interventional ImagingCitation Excerpt :Additional work evaluating ovarian cancer heterogeneity at the genomic level has been done. Studies have shown that wide inter-tumoral heterogeneity exists at the genomic level between primary ovarian cancer and peritoneal implants [52–58]. Supporting these findings, a preliminary analysis of a small cohort of patients who underwent MRI examination has revealed that ovarian tumors and metastatic peritoneal implants are already phenotypically heterogeneous at the time of diagnosis [59].
ITRAQ-based quantitative proteomics reveals myoferlin as a novel prognostic predictor in pancreatic adenocarcinoma
2013, Journal of ProteomicsCitation Excerpt :In our study, we revealed that overexpression of myoferlin (MYOF) was correlated with high tumor grade in PAC by iTRAQ labeling combined with 2D LC–MS/MS. Myoferlin has been identified as a membrane-associated protein important for muscle development and regeneration [7,8]. Immunohistochemical evidence available from the Human Protein Atlas [9] suggests that myoferlin is strongly expressed in several cancer types including colorectal, breast, ovarian, cervical, endometrial, thyroid, stomach, pancreatic, and liver cancers [10–20]. Eisenberg et al. [21] used a combination of mathematical modeling and experimental validation to uncover myoferlin as a cancer protein, which could be involved in regulating cancer cell invasion.
Functional Enrichment Analysis of Tumor Microenvironment–Driven Molecular Alterations That Facilitate Epithelial-to-Mesenchymal Transition and Distant Metastasis
2024, Bioinformatics and Biology InsightsVariable number tandem repeats mediate the expression of proximal genes
2021, Nature Communications
Supported in part by the Minnesota Ovarian Cancer Alliance, the Minnesota Medical Foundation, and the National Institutes of Health, RO1CA106878 (APNS).